Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 14/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486121 | 0.87 | KDM4E (0.42) | FYNKDM4EALDH1A1 | |
| SCHEMBL3486401 | 0.84 | DYRK1A (0.43) | FYN | |
| Trifluoroacetic Acid SCHEMBL3486475 | 0.80 | MAP3K5 (0.51) | FYNPOLB | |
| SCHEMBL3487008 | 0.79 | PIK3CD (0.39) | KDM4EALDH1A1SMN1; SMN2RXFP1NPC1 | |
| SCHEMBL13498808 | 0.79 | MAP3K5 (0.55) | FYNKDM4EPOLB | |
| SCHEMBL3486636 | 0.78 | KIF11 (0.38) | KDM4E | |
| SCHEMBL23535587 | 0.74 | FYN (0.64) | FYNKDM4EALDH1A1SMN1; SMN2RXFP1 | |
| SCHEMBL3486521 | 0.72 | ALDH1A3 (0.41) | KDM4EALDH1A1RXFP1NPC1RAB9A | |
| SCHEMBL12664401 | 0.70 | FYN (0.55) | FYNKDM4EALDH1A1SMN1; SMN2POLB | |
| SCHEMBL13498805 | 0.69 | MAP3K5 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | FYN 420/4885KDM4E 898/4885ALDH1A1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.